Image 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …”

Table 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …”

Image 4_Prediction of major adverse cardiovascular events following ST-segment elevation myocardial infarction using cardiac obesity marker—epicardial adipose tissue mass index: a... by Zeyan Liu (3748747)

“…Background<p>Although reperfusion therapy has led to improvements in the acute phase of ST-segment elevation myocardial infarction (STEMI), the incidence of major adverse cardiovascular events (MACE) following STEMI has not significantly decreased. The accumulation of epicardial adipose tissue (EAT) may be associated with poorer STEMI prognosis and could serve as a potential prognostic marker. …”

Image 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …”

Table 7_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …”

Table 8_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …”

Table 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …”

Image 2_Prediction of major adverse cardiovascular events following ST-segment elevation myocardial infarction using cardiac obesity marker—epicardial adipose tissue mass index: a... by Zeyan Liu (3748747)

“…Background<p>Although reperfusion therapy has led to improvements in the acute phase of ST-segment elevation myocardial infarction (STEMI), the incidence of major adverse cardiovascular events (MACE) following STEMI has not significantly decreased. The accumulation of epicardial adipose tissue (EAT) may be associated with poorer STEMI prognosis and could serve as a potential prognostic marker. …”

Image 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …”

Image 5_Prediction of major adverse cardiovascular events following ST-segment elevation myocardial infarction using cardiac obesity marker—epicardial adipose tissue mass index: a... by Zeyan Liu (3748747)

“…Background<p>Although reperfusion therapy has led to improvements in the acute phase of ST-segment elevation myocardial infarction (STEMI), the incidence of major adverse cardiovascular events (MACE) following STEMI has not significantly decreased. The accumulation of epicardial adipose tissue (EAT) may be associated with poorer STEMI prognosis and could serve as a potential prognostic marker. …”

Table 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …”

Table 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …”

Inflammatory markers correlate with lymphocytes infiltrating and predict immunotherapy prognosis for esophageal cancer by Bei Wang (116772)

“…</p> <p><b>Results:</b> Decreased inflammation was found to be associated with increased CD3⁺ and CD8⁺ T-cell infiltration and a better prognosis. …”

Image 1_Prediction of major adverse cardiovascular events following ST-segment elevation myocardial infarction using cardiac obesity marker—epicardial adipose tissue mass index: a... by Zeyan Liu (3748747)

“…Background<p>Although reperfusion therapy has led to improvements in the acute phase of ST-segment elevation myocardial infarction (STEMI), the incidence of major adverse cardiovascular events (MACE) following STEMI has not significantly decreased. The accumulation of epicardial adipose tissue (EAT) may be associated with poorer STEMI prognosis and could serve as a potential prognostic marker. …”

Table 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …”

Image 1_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …”

Accommodating talker variability in noise (Zhang & Peng, 2025) by Kaile Zhang (21763791)

“…Notably, listeners with lower Stroop interference scores demonstrated better extrinsic normalization in BMN and at 10 and 0 dB SNRs.…”

Image 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …”

Table 1_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …”

Image 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …”